Research
Hormonal
Semaglutide (2.4 mg weekly) induces significant weight loss (approx. 14.9%) in adults with obesity, superior to Liraglutide (3 mg daily) and placebo.
Semaglutide 2.4mg once weekly is a highly effective treatment for obesity, producing nearly 15% weight loss in clinical trials. It works by targeting brain pathways that control appetite. While it requires weekly injections, its efficacy is superior to older daily GLP-1 medications.
StrongSupportsVERY_HIGH confidence
Dopo 68 settimane, i soggetti in trattamento con semaglutide 2.4 mg ottenevano un decremento ponderale del 14,9% a confronto con il 2,4% del gruppo placebo... I benefici sul peso corporeo di semaglutide ad alto dosaggio sembrano essere superiori a quelli ottenibili con liraglutide 3 mg...
Why this rating
Based on Phase 3 STEP trials with large sample sizes.
Source
Terapia farmacologica dell’obesità: attualità e prospettive future
Federica Vinciguerra et al. · L Endocrinologo · 2022
narrative_reviewCited 2×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →